A high 18 F-FDOPA uptake is associated with a slow growth rate in diffuse Grade II-III gliomas

• Published in: British journal of radiology 2018-04, Vol.91 (1084), p.20170803
• Main Authors: Isal, Sibel, Gauchotte, Guillaume, Rech, Fabien, Blonski, Marie, Planel, Sophie, Chawki, Mohammad B, Karcher, Gilles, Marie, Pierre-Yves, Taillandier, Luc, Verger, Antoine
• Format: Article
• Language: English
• Subjects: Adult; Brain Neoplasms - diagnostic imaging; Brain Neoplasms - metabolism; Brain Neoplasms - pathology; Cancer; Dihydroxyphenylalanine - analogs & derivatives; Dihydroxyphenylalanine - pharmacokinetics; Disease Progression; Female; Glioma - diagnostic imaging; Glioma - metabolism; Glioma - pathology; Humans; Life Sciences; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Grading; Pilot Projects; Positron-Emission Tomography - methods; Prognosis; Radiopharmaceuticals - pharmacokinetics; Retrospective Studies
• ISSN: 0007-1285; 1748-880X
• DOI: 10.1259/bjr.20170803

In diffuse Grade II-III gliomas, a high 3,4-dihydroxy-6-( F)-fluoro-L-phenylalanine ( F-FDOPA) positron emission tomography (PET) uptake, with a standardized uptake value (SUV )/contralateral brain tissue ratio greater than 1.8, was previously found to be consistently associated with the presence of an isocitrate dehydrogenase (IDH) mutation, whereas this mutation is typically associated with a better prognosis. This pilot study was aimed to ascertain the prognostic value of this high F-FDOPA uptake in diffuse Grade II-III gliomas with regard to the velocity of diameter expansion (VDE), which represents an established landmark of better prognosis when below 4 mm per year. 20 patients (42 ± 10 years, 10 female) with newly-diagnosed diffuse Grade II-III gliomas (17 with IDH mutation) were retrospectively included. All had a F-FDOPA PET, quantified with SUV ratio, along with a serial MRI enabling VDE determination. SUV ratio was above 1.8 in 5 patients (25%) all of whom had a VDE